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The authors’ objective in this study was to estimate the changes in serum folate and homocysteine concentration
that resulted from 6 weeks of supplementation with folic acid. A randomized, double-blind, placebo-controlled,
dose-response trial with a parallel-group design was conducted. A total of 133 participants aged 60–90 years (70%
female, 19% nonwhite) were assigned to receive 0, 100, 400, 1,000, or 2,000 lg/day of folic acid for 6 weeks. Data
were collected in the United States between June and September 1996. At baseline, median serum folate and
plasma homocysteine concentrations were 5.7 ng/mL (interquartile range (25th–75th percentiles), 4.1–7.8) and 8.3
lmol/L (interquartile range, 7.1–10.0), respectively. As the folic acid dose increased, serum folate levels increased
(P-trend < 0.001). There was no dose-response relation with homocysteine level among all participants. In
analyses restricted to persons with the lowest serum folate concentration (<4.5 ng/mL) at baseline, there was
a trend (P ¼ 0.06) toward decreased homocysteine levels with increasing folic acid dose. In healthy, older adults
with adequate folate status, folic acid supplementation is not beneﬁcial for homocysteine reduction. However, for
older adults with low serum folate levels, supplementation will improve folate status and may be beneﬁcial for
lowering homocysteine concentrations.
adult; dietary supplements; folic acid; homocysteine
Abbreviation: eGFR, estimated glomerular ﬁltration rate.
Low folate concentration is associated with increased ho-
mocysteine concentration (1, 2), and homocysteine concen-
tration increases with age (3, 4). By lowering homocysteine
concentration, folic acid supplementation may prevent
colorectal cancer (5, 6), cognitive decline (7–9), vascular
dementia (10), and possibly cardiovascular disease (11–
13), although trial results related to cardiovascular disease
prevention have been disappointing (14–22). The impor-
tance of folic acid supplementation in disease prevention
remains widely debated.
Folic acid supplementation may be particularly important
in ensuring adequate folate status in vulnerable populations
such as older adults. Folate deficiency in older adults has
been documented, with estimates as high as 40% in the
United States (3) and 30%–50% in the Netherlands, Bel-
gium, and Germany (23). Age-related increases in homocys-
teine levels are related to suboptimal intake and absorption
of key vitamin B cofactors or substrates for homocys-
teine metabolism (3), reduced activity of homocysteine-
metabolizing enzymes (24), and declining kidney function
(25). Moreover, older adults with elevated homocysteine
levels (14.3 lmol/L) have increased rates of all-cause
and cardiovascular disease mortality (4). Pharmacologic
doses of >2,000 lg/day of folic acid lower homocysteine
concentration in older adults, but few dose-response studies
have been conducted in this population using low-to-mod-
erate doses (23, 26).
Our aim in this placebo-controlled dose-response trial
was to estimate the changes in serum folate and plasma
homocysteine concentration that result from supplementa-
tion with a wide range of doses of folic acid (0, 100, 400,
1,000, and 2,000 lg/day) in older adults in the United States.
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MATERIALS AND METHODS
This folic acid supplementation study was a randomized,
double-blind, placebo-controlled dose-response trial with
a parallel-group design. The trial was conducted at the
Johns Hopkins Medical Institutions in Baltimore, Mary-
land, in 1996. The study protocol was approved by the
institutional review board of the Johns Hopkins Medical
Institutions. Each participant provided written informed
consent.
Participants
Healthy, community-dwelling adults aged 60–90 years
who were not taking multivitamins or B vitamins were
enrolled. To participate, prior supplement users had to dis-
continue use of multivitamins, folic acid, and pyridoxine
for at least 8 weeks before enrollment. Other exclusion
criteria were: 1) intramuscular use of vitamin B12; 2) sei-
zure disorder; 3) pernicious anemia; or 4) chronic use of
antifolate drugs (e.g., methotrexate, sulfa antibiotics). Re-
cruitment was completed between June and August of
1996, and follow-up ended in September 1996. Partici-
pants were recruited from a local Baltimore retirement
community and from lists of prior study participants and
screenees.
Data collection
Data were collected at 3 clinic visits—screening, baseline,
and a follow-up visit 6 weeks after baseline. At the screening
visit, eligibility was determined, and informed consent
was obtained. If the person was eligible, a questionnaire
on medical history and sociodemographic factors was self-
administered before the baseline visit, along with a validated
food frequency questionnaire (27). Height and weight were
also measured. At the baseline visit, randomization was
completed and a fasting venous blood sample was obtained.
At the follow-up visit, another fasting venous blood sample
was obtained. Participants were asked about vitamin use to
ensure that folic acid and other B vitamins were not taken
during the intervention period. Plasma homocysteine and
serum folate, vitamin B12, and creatinine concentrations
were measured after an overnight fast. Samples collected
for determination of plasma homocysteine level were drawn
into tubes containing ethylenediaminetetraacetic acid, im-
mediately placed on ice, and centrifuged within 90 minutes.
Blood samples for determination of serum folate level were
drawn and kept at room temperature for at least 15 minutes
and allowed to clot before centrifugation. All aliquots of
plasma and serum were frozen at 70C until analysis. Di-
etary intake of folate was determined from the Block food
frequency questionnaire. Body mass index was calculated as
weight (kilograms) divided by height squared (meters
squared). We calculated estimated glomerular filtration rate
(eGFR) as a marker of kidney function using the 4-variable
simplified Modification of Diet in Renal Disease Study equa-
tion (28). eGFR is expressed in mL/minute/1.73 m2. The
equation for eGFR is 186 3 (PCr)
1.154 3 (age)0.203 3
(0.742 if female)3 (1.210 if black).
Randomization and intervention
At the baseline visit, simple randomization was carried
out, with no restrictions. Participants were assigned on an
individual basis to an intervention dose in blocks of 10. The
allocation scheduled was concealed, and the study coordi-
nator was unaware of the next assignment in the sequence.
Participants were randomized to one of 5 dose groups of
daily folic acid supplementation. Doses used were 0, 100,
400, 1,000, and 2,000 lg and were comparable to the refer-
ence category (0 lg) and 1) the anticipated increase in di-
etary folic acid to be achieved by folic acid fortification (100
lg); 2) the typical dose of folic acid in multivitamin supple-
ments (400 lg); 3) the upper limit of the Institute of Med-
icine Dietary Reference Intakes (1,000 lg) (29); and
4) a pharmacologic dose (2,000 lg), respectively. The
2,000-lg dose is twice the upper limit of the 1,000 lg/day
recommended by the Institute of Medicine Dietary Refer-
ence Intakes (29). This upper limit is set because of con-
cerns about masking vitamin B12 deficiency and its
neurologic consequences, but this dose is currently used
pharmacologically. Serum vitamin B12 was measured at
baseline, and no participants were found to have inadequate
vitamin B12 status (170–250 pg/mL). At the baseline clinic
visit, participants were given a 6-week supply of pills and
instructions on pill-taking. Participants remained on the
same dose throughout the entire study. Study pills were pro-
vided by Whitehall-Robins Healthcare (Madison, New Jer-
sey). Participant compliance in taking the study capsules
was measured by pill count. Blood folate levels are also
a marker of folic acid intake.
Laboratory procedures
Folate and homocysteine assays were conducted at the
Jean Mayer US Department of Agriculture Human Nutrition
Research Center on Aging at Tufts University in Boston,
Massachusetts, in 1996. Serum folate concentration was
measured by means of radio-protein binding Quantaphase
II (Bio-Rad Laboratories, Hercules, California). Serum sam-
ples were analyzed together in a single run. Intraassay var-
iability for folate using the Quantaphase II was 11%.
Intraassay variability for vitamin B12 was 11%.
Plasma homocysteine concentration was measured by
high-performance liquid chromatography with fluorometric
detection. Samples were assayed over the course of 3 runs
with well-accepted variability. The intraassay variability
was 4%, and the interassay variabilities were 7%, 12%,
and 6%.
Statistical analysis
Statistical analyses were performed using SAS software
(version 9.1; SAS Institute, Inc., Cary, North Carolina) and
Stata software (release 8.0l; Stata Corporation, College Sta-
tion, Texas). Changes in serum folate and homocysteine
concentrations between baseline and the follow-up visits
were the primary variables of interest. Homocysteine values
were not normally distributed. To minimize the potential
influence of outliers, we display median values with
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interquartile ranges (25th–75th percentiles). Change in ho-
mocysteine level from baseline to follow-up was calculated.
Median changes in homocysteine concentration are pre-
sented for each dose group. Nonparametric tests were used.
We tested the hypothesis that there was a difference in
change in homocysteine level among the 5 dose groups
(SAS npar1way command) using the Kruskal-Wallis test.
The Kruskal-Wallis test is the nonparametric analog of the
1-way analysis of variance test. Pairwise comparisons be-
tween active dose groups and the placebo group were ex-
amined (SAS npar1way command) using the exact
Wilcoxon rank-sum test. The rank-sum test is the nonpara-
metric analog of the independent 2-sample t test. Tests for
a trend in homocysteine reduction across the 5 dose groups
were also conducted (Stata nptrend command). Statistical
significance was set at P < 0.05. To detect a 2.5-lmol/L
difference in homocysteine concentration between the pla-
cebo group and each active dose group, a sample size of 25
people was needed for each of the 5 study groups at a¼ 0.05
(2-sided) with 80% power.
RESULTS
Of the 176 screened participants, 133 were randomized
(Figure 1). The follow-up rate was 100%, and analyses were
conducted using all randomized participants. As shown in
Table 1, participants were mostly female, white, non-
smokers, nondrinkers, and nonusers of vitamins. The me-
dian age was 76 years. There were slightly more African
Americans in the 100-lg and 400-lg dose groups than in the
other 3 groups. All participants were compliant on the basis
of having missed no more than 1 study capsule per week.
Blood folate levels also increased in persons in the active
dose groups, corroborating compliance findings obtained by
pill count.
Table 2 displays serum folate and homocysteine concen-
trations before and after the 6-week folic acid intervention,
within-group changes by folic acid intervention group, and
between-group differences (active doses vs. placebo). At
baseline, there were no significant differences among the
groups in serum folate or homocysteine concentrations. Dif-
ferences were seen among the 5 dose groups for change in
serum folate level (P < 0.001, Kruskal-Wallis test) but not
for change in homocysteine level (P ¼ 0.42, Kruskal-Wallis
test). For pairwise comparisons of active dose groups versus
placebo, except for the comparison of 100 lg/day vs. 0 lg/
day, there were differences in change in serum folate level.
In contrast, there were no differences in change in homo-
cysteine level for pairwise comparisons of groups with ac-
tive doses versus placebo. There was a significant trend
toward increased serum folate with increasing folic acid
dose (P < 0.001), but there was no trend in homocysteine
Interested and screened for
eligibility (n = 176)
Randomized (n = 133)
Excluded
(n = 0)
Analyzed
(n = 26)
Excluded
(n = 0)
Analyzed
(n = 27)
Excluded
(n = 0)
Analyzed
(n = 27)
Excluded 
(n = 0)
Analyzed
(n = 26)
Excluded 
(n = 0)
Analyzed
(n = 27)
Excluded because they
did not meet eligibility
criteria (n = 27)
Dropped out prior to
randomization (n = 16)
(n
Assigned to
placebo
group
= 26)
Assigned to 
100 µg/day
of folic acid
(n = 27)
Assigned to
400 µg/day
of folic acid
(n = 27)
Assigned to
1,000 µg/day
of folic acid
(n = 26)
Assigned to
2,000 µg/day
of folic acid
(n = 27)
Figure 1. Participant ﬂow through each stage of a 6-week trial of folic acid supplementation and change in serum folate and plasma homocysteine
concentrations among adults aged 60–90 years, Baltimore, Maryland, 1996.
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Table 1. Baseline Demographic and Clinical Characteristics of Adults Aged 60–90 Years in a 6-Week Trial of Folic Acid Supplementation and Change in Serum Folate and Plasma
Homocysteine Concentrations, by Folic Acid Dose Group, Baltimore, Maryland, 1996a
All
Participants
(n 5 133)
Placebo Group
(0 mg/day)
(n 5 26)
Folic Acid Supplement Dose, mg/day
100 (n 5 27) 400 (n 5 27) 1,000 (n 5 26) 2,000 (n 5 27)
No. %
Median
(IQRb)
No. %
Median
(IQR)
No. %
Median
(IQR)
No. %
Median
(IQR)
No. %
Median
(IQR)
No. %
Median
(IQR)
Demographic factors
Female sex 93 70 21 81 21 78 17 63 17 65 17 63
Black race 20 15 2 8 6 22 6 22 4 15 2 7
Current smoker 9 7 3 12 0 0 2 7 1 4 3 11
Prior multivitamin
user
41 31 7 27 7 26 8 30 9 35 10 37
Age, years 76 (71–81) 75.5 (73–84) 75 (69–80) 76 (69–82) 75.5 (71–81) 77 (72–80)
Clinical characteristics
Body mass indexc 27.1 (24.2–30.1) 26.0 (22.5–27.8) 27.7 (24.8–31.1) 27.1 (24.2–31.3) 27.4 (25.4–30.8) 27.4 (24.0–31.6)
Dietary folate intake,
lg/day
282 (221–349) 310 (248–417) 244 (195–309) 289 (221–341) 281 (206–364) 302 (184–388)
Alcohol consumption,
drinks/week
0 (0–1) 0 (0–1) 0 (0–2) 0 (0–1) 0 (0–2) 0 (0–2)
Serum vitamin B12
concentration,
pg/mL
407 (308–480) 425 (294–477) 393 (308–526) 423 (315–475) 356 (305–493) 424 (357–471)
Serum creatinine
concentration,
mg/dL
1.0 (0.8–1.2) 1.0 (0.8–1.0) 0.9 (0.8–1.1) 1.1 (0.9–1.2) 1.0 (0.9–1.2) 0.9 (0.8–1.1)
Estimated glomerular
ﬁltration rated,
mL/minute/1.73 m2
65 (58–75) 65 (57–75) 73 (57–81) 65 (57–76) 64 (57–72) 72 (59–79)
Abbreviation: IQR, interquartile range.
a There were no statistically signiﬁcant differences among groups at baseline with regard to demographic factors, clinical characteristics, or outcome variables (P > 0.05).
b 25th–75th percentiles.
c Weight (kg)/height (m)2.
d Calculated using the Modiﬁcation of Diet in Renal Disease Study (28) 4-variable simple equation variables (P > 0.05).
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Table 2. Homocysteine and Serum Folate Concentrationsa at Baseline and at the End of a 6-Week Intervention Period Involving Folic Acid Supplementation Among Adults Aged 60–90
Years, Within-Group Changes by Folic Acid Dose Group, and Between-Group Comparisons (Active Dose vs. Placebo), Baltimore, Maryland, 1996
All
Participants
(n 5 133)
Placebo Group
(0 mg/day)
(n 5 26)
Folic Acid Supplement Dose, mg/day
P-Trend
100 (n 5 27) 400 (n 5 27) 1,000 (n 5 26) 2,000 (n 5 27)
Median IQRb Median IQR Median IQR Median IQR Median IQR Median IQR
Week 0
Folate RIA, ng/mL 5.7 4.1–7.8 5.2 4.1–7.4 4.8 3.7–6.7 6.7 3.7–8.1 6.0 4.1–7.7 6.6 5.4–7.9
Homocysteine,
lmol/L
8.3 7.1–10.0 9.1 7.1–11.6 7.8 7.2–9.2 8.1 7.4–9.9 9.2 7.0–10.6 7.9 6.9–9.1
Week 6
Folate RIA, ng/mL 5.4 3.8–6.2 7.0 5.4–9.4 12.4 9.6–16.7 16.1 12.4–32.6 16.4 10.7–65.5
Homocysteine,
lmol/L
8.0 6.9–10.4 7.7 6.9–9.0 8.5 7.5–9.7 7.8 6.6–9.4 7.7 6.4–8.9
Within-group change
postintervention
Folate RIA, ng/mL 0.6 1.2 to 1.0 2.2 0.9 to 3.2 6.0 3.3 to 11.6 10.8 6.3 to 27.3 8.2 2.6 to 60.5 <0.001
Homocysteine, lmol/L 0.5 1.3 to 0.4 0.2 1.2 to 0.5 0.1 1.0 to 1.0 1.0 1.7 to 0.1 0.5 1.1 to 0.9 0.75
Between-group change
postintervention (active
dose vs. placebo)
Median 95% CI Median 95% CI Median 95% CI Median 95% CI
Folate RIA, ng/mL 2.8 0.63, 4.93 6.6 4.45, 8.74 12.5 10.3, 14.6 8.8 6.6, 11.0
Homocysteine, lmol/L 0.4 0.47, 1.21 0.7 0.17, 1.51 0.4 1.28, 0.42 0.1 2.9, 0.39
Abbreviations: CI, conﬁdence interval; IQR, interquartile range; RIA, radioimmunoassay.
a To convert ng/mL to nmol/L, multiply by 2.27.
b 25th–75th percentiles.
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reduction for increasing doses of folic acid. The correlation
of change in homocysteine with change in serum folate was
not significant (Pearson’s correlation coefficient: r ¼ 0.05;
P ¼ 0.61).
Table 3 shows results from analyses restricted to persons
in the lowest tertile of serum folate concentration at baseline
(<4.5 ng/mL). Similar to the overall group, differences were
seen in this subgroup among the 5 dose groups for change in
serum folate level (P < 0.001, Kruskal-Wallis test) but not
for change in homocysteine level (P ¼ 0.34, Kruskal-Wallis
test). There were significant differences in serum folate con-
centration for all active dose groups versus placebo, except
for the 100-lg/day versus 0-lg/day comparison. However,
there were no significant differences in homocysteine con-
centration for pairwise comparisons of active doses versus
placebo. Serum folate concentrations significantly increased
as folic acid dose increased (P-trend < 0.001). In contrast
to the findings in the entire study population, there was a
borderline-significant trend in homocysteine reduction with
increasing doses of folic acid.
Table 4 shows results from analyses restricted to persons
in the highest tertile of plasma homocysteine concentration
at baseline. The change in serum folate level was different
among the 5 dose groups (P < 0.001), while there was no
difference in change in homocysteine level (P ¼ 0.50). The
change in serum folate level was different for active-dose
groups versus placebo, except between the 100-lg/day
group and the placebo group, but there were no differences
in change in homocysteine for active doses versus placebo.
There was a significant trend toward an increased serum
folate concentration with increasing folic acid dose (P <
0.001). There was no trend in homocysteine reduction for
increasing doses of folic acid. Note that baseline kidney
function in this subgroup, as determined by eGFR, was sim-
ilar to that in the entire study population. The median eGFR
concentration among all participants was 65 mL/minute/
1.73 m2 (interquartile range, 58–75) as compared with
64 mL/minute/1.73 m2 (interquartile range, 52–73) among
persons in the highest tertile of plasma homocysteine.
DISCUSSION
In this dose-response trial of healthy, older persons, we
found that serum folate concentration progressively in-
creased with higher doses of supplemental folic acid.
Among all participants and in those with the highest homo-
cysteine concentrations at baseline, there was no dose-
response relation between folic acid intake and homocysteine
level. When analyses were restricted to persons with the
lowest plasma folate concentrations at baseline, there was
a borderline-significant trend in homocysteine reduction with
increasing doses of folic acid.
Our finding of an increase in serum folate concentration
with increasing folic acid intake is consistent with results
from observational studies (30, 31), as well as randomized
clinical trials of fortified foods (32–34) or supplements (35–
37). Most relevant to our findings are results from another
dose-response study carried out in older adults (26), where 4
weeks of supplementation with placebo and folic acid at
doses of 100 lg/day and 400 lg/day produced increases in
serum folate concentrations.
Our results complement those of other studies examining
the homocysteine-lowering effect of folic acid. These in-
clude 2 meta-analyses (2, 38) and 5 dose-response trials
(23, 26, 35–37). Results from the 2 dose-response trials that
were conducted in healthy, older adults are most relevant to
our trial (23, 26). Although our results are in contrast to
those of these 2 trials, they are consistent with those of
the first Homocysteine Lowering Trialists’ Collaboration
meta-analysis (2), which showed no differences in the
homocysteine-lowering effect among higher folic acid
doses (800, 1,000, or 2,000 lg/day). In this meta-analysis,
the investigators concluded that the reduction in homocys-
teine concentration achieved was comparable (~25%) for
folic acid doses of 500–1,000 lg/day, 1,000–3,000 lg/day,
and>3,000 lg/day (2). The second Homocysteine Lowering
Trialists’ Collaboration meta-analysis included lower doses
of folic acid (<500 lg/day) and found differences in their
homocysteine-lowering effects (38). Differences were seen
between 200 lg/day and 400 lg/day and between 400 lg/
day and 800 lg/day. These results for lower doses of folic
acid are in contrast to our findings. Unlike our study, the
meta-analyses included persons from a wide age range (17–
92 years) with a median preintervention homocysteine con-
centration of 10.5 lmol/L.
There are 3 potential reasons for the lack of effect of folic
acid on homocysteine levels seen in our study. First, our
study population was healthier than expected, with rela-
tively high serum folate concentrations and low homo-
cysteine concentrations at baseline. The degree of
homocysteine response to folic acid intervention depends
on preintervention concentrations of both folate and homo-
cysteine. There is also a nonlinear relation between folate
and mean homocysteine levels and a plateau beyond which
homocysteine concentrations remain stable (1). Our trial
baseline homocysteine concentrations (8.3 lmol/L) were
lower than those seen in the dose-response study by van
Oort et al. (26) (range of 10.9–12.0 lmol/L by dose group)
and in the dose-response study by Rydlewicz et al. (23)
(range of 9.5–10.8 lmol/L by dose group). We conducted
subgroup analyses in this study to evaluate the effect of the
intervention in persons with the lowest preintervention con-
centrations of folate. We did not have sufficient statistical
power for subgroup analyses; thus, sample sizes for these
analyses were small. However, we found a near-significant
(P¼ 0.06) dose response among persons in the lowest tertile
of serum folate concentration at baseline. Furthermore, the
greatest homocysteine reductions in this study were seen
among persons with the highest baseline homocysteine con-
centrations who took 100 lg/day (2.3 lmol/L) or 400 lg/
day (2.8 lmol/L).
The second potential reason for the lack of effect of folic
acid in our study is the possibility that the homocysteine-
lowering effect of folic acid may have been attenuated by
participants’ intake of fortified foods during the fortification
transition period. Early fortification of foods may have oc-
curred in the Baltimore area. Although we intended to start
this study prior to fortification, industry initiation of fortifi-
cation was done earlier than the mandate for 1998 and
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Table 3. Homocysteine and Serum Folate Concentrationsa Before and After a 6-Week Intervention Period Involving Folic Acid Supplementation Among Adults Aged 60–90 Years and
Median Changes After Intervention by Intervention Group for Persons in the Lowest Tertile (4.5 ng/L) of Baseline Serum Folate Concentration, Baltimore, Maryland, 1996
All
Participants
(n 5 43)
Placebo Group
(0 mg/day)
(n 5 9)
Folic Acid Supplement Dose, mg/day
P-Trend
100 (n 5 11) 400 (n 5 10) 1,000 (n 5 10) 2,000 (n 5 3)
Median IQRb Median IQR Median IQR Median IQR Median IQR Median IQR
Week 0
Folate RIA, ng/mL 3.7 3.0–4.1 3.7 3.0–4.1 3.7 2.1–3.9 3.2 2.5–3.9 3.5 3.1–4.3 3.1 2.9–4.5
Homocysteine, lmol/L 11.0 8.9–12.8 11.0 8.9–12.8 8.9 7.5–10.8 9.2 7.8–12.6 10.3 9.2–11.2 9.1 8.5–22.2
Week 6
Folate RIA, ng/mL 4.2 3.6–5.6 5.6 4.4–8.0 8.6 6.6–12.4 16.5 12.4–25.7 84.2 7.0–105.5
Homocysteine, lmol/L 10.1 7.2–12.0 8.5 6.9–9.8 8.8 7.7–9.5 9.1 7.7–9.7 6.4 5.3–20.7
Within-group change
postintervention
Folate RIA, ng/mL 1.0 0.1 to 1.8 2.5 2.0 to 3.5 5.6 3.3 to 8.5 13.0 9.7 to 22.6 80.6 2.4 to 102.4 <0.001
Homocysteine, lmol/L 0.8 1.4 to 0.3  0.4 2.3 to 0.7 1.2 3.2 to 0.5 1.6 2.0 to 1.0 2.1 3.8 to 1.5 0.06
Between-group change
postintervention (active
dose vs. placebo)
Median 95% CI Median 95% CI Median 95% CI Median 95% CI
Folate RIA, ng/mL 1.6 0.4, 3.6 4.8 1.7, 8.0 13.1 9.1, 17.0 79.6 75.8, 83.4
Homocysteine, lmol/L 0.4 1.7, 2.5 0.6 3.0, 1.8 0.7 2.0, 0.6 1.3 3.9, 1.3
Abbreviations: CI, conﬁdence interval; IQR, interquartile range; RIA, radioimmunoassay.
a To convert ng/mL to nmol/L, multiply by 2.27.
b 25th–75th percentiles.
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Table 4. Homocysteine and Serum Folate Concentrationsa Before and After a 6-Week Intervention Period Involving Folic Acid Supplementation Among Adults Aged 60–90 Years and
Median Changes After Intervention by Intervention Group for Persons in the Highest Tertile (9.19 mmol/L) of Baseline Plasma Homocysteine Concentration, Baltimore, Maryland, 1996
All
Participants
(n 5 45)
Placebo Group
(0 mg/day)
(n 5 12)
Folic Acid Supplement Dose, mg/day
P-Trend
100 (n 5 6) 400 (n 5 9) 1,000 (n 5 12) 2,000 (n 5 6)
Median IQRb Median IQR Median IQR Median IQR Median IQR Median IQR
Week 0
Folate RIA, ng/mL 4.4 3.3–6.4 4.6 3.8–6.4 4.1 2.1–4.5 3.7 2.5–8.7 4.4 3.5–6.3 5.8 4.9–7.6
Homocysteine, lmol/L 11.0 9.9–12.6 11.7 10.5–12.7 11.5 10.4–13.2 11.2 9.9–12.6 10.8 9.5–11.1 11.5 9.6–18.5
Week 6
Folate RIA, ng/mL 3.8 3.3–5.5 6.8 4.9–10.0 10.8 6.6–15.4 16.5 12.3–32.9 61.5 11.6–105.8
Homocysteine, lmol/L 9.7 8.3–11.7 9.1 8.8–9.8 10.0 9.2–11.1 9.1 8.3–9.7 9.7 8.3–18.2
Within-group change
postintervention
Folate RIA, ng/mL 0.7 3.3 to 0.6 3.4 0.9 to 6.2 3.3 3.1 to 9.4 13.0 7.8 to 28.7 52.5 5.9 to 102.4 <0.001
Homocysteine, lmol/L 0.9 2.1 to 0.1 2.3 4.2 to 1.3 2.8 3.2 to 0.2 1.6 2.1 to 0.4 1.0 1.5 to 0.7 0.84
Between-group change
postintervention (active
dose vs. placebo)
Median 95% CI Median 95% CI Median 95% CI Median 95% CI
Folate RIA, ng/mL 4.5 1.7, 10.7 4.0 1.1, 6.9 14.7 8.4, 21.0 98.9 87.3, 110.5
Homocysteine, lmol/L 1.4 5.3, 2.5 1.9 4.3, 0.4 0.5 1.8, 0.8 0.2 1.7, 1.2
Abbreviations: CI, conﬁdence interval; IQR, interquartile range; RIA, radioimmunoassay.
a To convert ng/mL to nmol/L, multiply by 2.27.
b 25th–75th percentiles.
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occurred throughout our data collection period. The extent
of the effect of fortification on our results is unknown, but it
is possible that it influenced our findings. Evidence from
clinical trials on cardiovascular disease suggests that forti-
fication has influenced the homocysteine-lowering effect of
folic acid (15, 16). Trials conducted in countries with man-
datory fortification show narrower differences in homocys-
teine outcomes for study groups than trials conducted in
countries without fortification (2, 38).
The third potential reason for the lack of effect of folic
acid in this study is the possibility that supplementation
with vitamin B6, B12, or B2 is also necessary for a reduction
in homocysteine levels to occur. There are 2 pathways in-
volved in homocysteine metabolism. One pathway is re-
methylation, and it requires folic acid and vitamin B12
coenzymes. The other pathway is transsulfuration, which
requires a vitamin B6 coenzyme. Riboflavin may also be
used in the metabolic cycle. Since folic acid fortification
began, there have been scientific reports suggesting that
other B vitamins have an important role in lowering ho-
mocysteine concentration (35, 39). More specifically, as-
sociations between vitamin intakes and homocysteine
levels have shifted from being primarily dependent on fo-
late status to being more dependent on B-vitamin status
(35, 39). Results from these studies suggested that the
homocysteine-lowering effect of a regimen including folic
acid and B vitamins was highly dependent on the action of
vitamin B12. In this study, we did not monitor intake of
vitamin B6, B12, or B2.
In summary, although no dose-response relation was seen
between folic acid supplementation and homocysteine con-
centration, our data indicate that healthy, older adults can
improve their folate status through supplementation. The
benefits, risks, and appropriate dose of folic acid supplemen-
tation continue to be investigated for various health out-
comes (40–42). These data suggest that a folic acid dose
as low as 100 lg/day is effective in raising serum folate
concentrations, and increasing folic acid dose leads to
greater increases in blood folate concentration, with no ev-
idence of a threshold. In the folic acid fortification era, daily
supplementation comparable to usual dietary intake or even
high-dose supplements does not lower homocysteine con-
centrations in healthy, older adults. Older adults with low
folate status may benefit from folic acid supplementation.
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